Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE

MA. D'Agostino, G. Schett, A. López-Rdz, L. Šenolt, K. Fazekas, R. Burgos-Vargas, J. Maldonado-Cocco, E. Naredo, P. Carron, AM. Duggan, P. Goyanka, M. Boers, C. Gaillez

. 2022 ; 61 (5) : 1867-1876. [pub] 20220505

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018465

OBJECTIVES: To investigate the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA using Power Doppler ultrasound. METHODS: The randomized, placebo-controlled, Phase III ULTIMATE study enrolled PsA patients with active ultrasound synovitis and clinical synovitis and enthesitis having an inadequate response to conventional DMARDs and naïve to biologic DMARDs. Patients were randomly assigned to receive either weekly subcutaneous secukinumab (300 or 150 mg according to the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The primary outcome was the mean change in the ultrasound Global EULAR and OMERACT Synovitis Score (GLOESS) from baseline to week 12. Key secondary endpoints included ACR 20 and 50 responses. RESULTS: Of the 166 patients enrolled, 97% completed 12 weeks of treatment (secukinumab, 99%; placebo, 95%). The primary end point was met, and the adjusted mean change in GLOESS was higher with secukinumab than placebo [-9 (0.9) vs -6 (0.9), difference (95% CI): -3 (-6, -1); one-sided P=0.004] at week 12. The difference in GLOESS between secukinumab and placebo was significant as early as one week after initiation of treatment. All key secondary endpoints were met. No new or unexpected safety findings were reported. CONCLUSION: This unique ultrasound study shows that apart from improving the signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid and significant reduction of synovitis in PsA patients. TRIAL REGISTRATION: ClinicalTrials.gov; NCT02662985.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018465
003      
CZ-PrNML
005      
20220804134801.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/keab628 $2 doi
035    __
$a (PubMed)34528079
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a D'Agostino, Maria Antonietta $u Department of Rheumatology, Catholic University of Sacred Heart, Roma, Italy $1 https://orcid.org/0000000253470060
245    10
$a Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE / $c MA. D'Agostino, G. Schett, A. López-Rdz, L. Šenolt, K. Fazekas, R. Burgos-Vargas, J. Maldonado-Cocco, E. Naredo, P. Carron, AM. Duggan, P. Goyanka, M. Boers, C. Gaillez
520    9_
$a OBJECTIVES: To investigate the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA using Power Doppler ultrasound. METHODS: The randomized, placebo-controlled, Phase III ULTIMATE study enrolled PsA patients with active ultrasound synovitis and clinical synovitis and enthesitis having an inadequate response to conventional DMARDs and naïve to biologic DMARDs. Patients were randomly assigned to receive either weekly subcutaneous secukinumab (300 or 150 mg according to the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The primary outcome was the mean change in the ultrasound Global EULAR and OMERACT Synovitis Score (GLOESS) from baseline to week 12. Key secondary endpoints included ACR 20 and 50 responses. RESULTS: Of the 166 patients enrolled, 97% completed 12 weeks of treatment (secukinumab, 99%; placebo, 95%). The primary end point was met, and the adjusted mean change in GLOESS was higher with secukinumab than placebo [-9 (0.9) vs -6 (0.9), difference (95% CI): -3 (-6, -1); one-sided P=0.004] at week 12. The difference in GLOESS between secukinumab and placebo was significant as early as one week after initiation of treatment. All key secondary endpoints were met. No new or unexpected safety findings were reported. CONCLUSION: This unique ultrasound study shows that apart from improving the signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid and significant reduction of synovitis in PsA patients. TRIAL REGISTRATION: ClinicalTrials.gov; NCT02662985.
650    _2
$a monoklonální protilátky $x škodlivé účinky $7 D000911
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a psoriatická artritida $x komplikace $x diagnostické zobrazování $x farmakoterapie $7 D015535
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-17 $7 D020381
650    12
$a synovitida $x diagnostické zobrazování $x farmakoterapie $7 D013585
650    _2
$a výsledek terapie $7 D016896
650    _2
$a ultrasonografie dopplerovská $7 D018608
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Schett, Georg $u Department of Internal Medicine 3 $u Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany
700    1_
$a López-Rdz, Alejandra $u Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico
700    1_
$a Šenolt, Ladislav $u Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic
700    1_
$a Fazekas, Katalin $u Department of Rheumatology, Miskolci Semmelweis Hospital and University Teaching Hospital, Miskolci, Hungary
700    1_
$a Burgos-Vargas, Ruben $u Department of Rheumatology, Hospital General de Mexico, Mexico City, Mexico
700    1_
$a Maldonado-Cocco, Jose $u School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
700    1_
$a Naredo, Esperanza $u Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
700    1_
$a Carron, Philippe $u Department of Rheumatology, Ghent University Hospital $u VIB Inflammation Research Centre, Ghent University, Ghent, Belgium
700    1_
$a Duggan, Anne-Marie $u Novartis Ireland Limited, Dublin, Ireland
700    1_
$a Goyanka, Punit $u Novartis Healthcare Pvt Ltd, Hyderabad, India
700    1_
$a Boers, Maarten $u Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Centre, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands $1 https://orcid.org/000000026969283X
700    1_
$a Gaillez, Corine $u Novartis Pharma AG, Basel, Switzerland
773    0_
$w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 61, č. 5 (2022), s. 1867-1876
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34528079 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134755 $b ABA008
999    __
$a ok $b bmc $g 1822174 $s 1169708
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 61 $c 5 $d 1867-1876 $e 20220505 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace